Publikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Biodonostia (20)

2023

  1. Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction

    Clinical Research in Cardiology

2022

  1. Clear Cell Renal Cell Carcinomas with Aggressive Behavior Display Low Intratumor Heterogeneity at the Histological Level

    Current Urology Reports, Vol. 23, Núm. 6, pp. 93-97

  2. Consensus statement on the use of alemtuzumab in daily clinical practice in Spain

    Neurologia, Vol. 37, Núm. 8, pp. 615-630

2019

  1. Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Aging, Vol. 11, Núm. 9, pp. 2874-2888

  2. Neoadjuvant metformin added to systemic therapy decreases the proliferative capacity of residual breast cancer

    Journal of Clinical Medicine, Vol. 8, Núm. 12

  3. The C allele of ATM rs11212617 associates with higher pathological complete remission rate in breast cancer patients treated with neoadjuvant metformin

    Frontiers in Oncology, Vol. 9, Núm. MAR

2018

  1. A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: The METTEN study

    Oncotarget, Vol. 9, Núm. 86, pp. 35687-35704

  2. High levels of intratumor heterogeneity characterize the expression of epithelial-mesenchymal transition markers in high-grade clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 27-30

  3. Loss of PD-L1 (SP-142) expression characterizes renal vein tumor thrombus microenvironment in clear cell renal cell carcinoma

    Annals of Diagnostic Pathology, Vol. 34, pp. 89-93

  4. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy

    Pathology Research and Practice, Vol. 214, Núm. 8, pp. 1110-1114

2017

  1. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2015

  1. A functional variant that affects exon-skipping and protein expression of SP140 as genetic mechanism predisposing to multiple sclerosis

    Human Molecular Genetics, Vol. 24, Núm. 19, pp. 5619-5627

2013

  1. Fine Mapping and Functional Analysis of the Multiple Sclerosis Risk Gene CD6

    PLoS ONE, Vol. 8, Núm. 4

  2. Identification of a functional variant in the KIF5A-CYP27B1-METTL1-FAM119B locus associated with multiple sclerosis

    Journal of Medical Genetics, Vol. 50, Núm. 1, pp. 25-33

2012

  1. ANKRD55 and DHCR7 are novel multiple sclerosis risk loci

    Genes and Immunity, Vol. 13, Núm. 3, pp. 253-257

  2. Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 983-990

  3. Replication study of 10 genes showing evidence for association with multiple sclerosis: Validation of TMEM39A, IL12B and CLBL genes

    Multiple Sclerosis Journal, Vol. 18, Núm. 7, pp. 959-965

2011

  1. Replication of top markers of a genome-wide association study in multiple sclerosis in Spain

    Genes and Immunity, Vol. 12, Núm. 2, pp. 110-115

2010

  1. The autoimmune disease-associated KIF5A, CD226 and SH2B3 gene variants confer susceptibility for multiple sclerosis

    Genes and Immunity, Vol. 11, Núm. 5, pp. 439-445

  2. Validation of the CD6 and TNFRSF1A loci as risk factors for multiple sclerosis in Spain

    Journal of Neuroimmunology, Vol. 223, Núm. 1-2, pp. 100-103